Jaguar Health, Inc. Announces Significant Amendments to Royalty Agreements and Warrant Termination

Key Points:

• Jaguar Health, Inc. (NASDAQ: JAGX) has entered into multiple material definitive agreements, including amendments to existing royalty agreements and termination of certain warrants.
• These changes involve principal investors: Uptown Capital, LLC, Streeterville Capital, LLC, and Iliad Research and Trading, L.P.
• The amendments result in immediate reductions to the company’s royalty repayment obligations, which are substantial and could impact Jaguar Health’s future cash flows and financial outlook.
• Warrants exercisable into 48,211 shares of common stock have been terminated, removing potential dilution for shareholders.

Detailed Analysis:

On March 6, 2026, Jaguar Health, Inc. took several notable steps to restructure its financial obligations and equity instruments:

• Royalty Interest Global Amendments:
  • Jaguar entered into Global Amendment No. 4 with Uptown Capital, LLC and Streeterville Capital, LLC regarding royalty interests originally issued in principal amounts of \$13.81 million (Uptown) and \$12 million (Streeterville), respectively.
  • Minimum Royalty Payments: Effective July 1, 2026, the company will pay a monthly royalty of either \$750,000 or the actual royalty payment due, whichever is greater.
  • Royalty Reduction: Upon execution of the amendments, the royalty repayment amounts are reduced by 10%. Uptown’s obligation is reduced to \$12,428,782.20 and Streeterville’s to \$11,125,282.54. This represents a significant reduction in cash outflows for Jaguar Health.
  • Jaguar Health confirms no events of default or material breaches exist under these royalty agreements, and the obligations remain valid and enforceable.
• Note Amendments:
  • Amendments were also made to 2021 and 2025 Notes between Jaguar Health, Streeterville Capital, LLC, and Napo Pharmaceuticals, Inc., further aligning payment terms and obligations.
• Warrant Termination Agreement:
  • Jaguar Health entered into an agreement with Uptown Capital, Streeterville Capital, and Iliad Research and Trading, L.P. to terminate warrants exercisable into a total of 48,211 shares of common stock. These warrants were previously issued to the investors.
  • The removal of these warrants eliminates a source of future dilution, which is an important positive for current shareholders.

Shareholder Considerations:

• Reduction in Royalty Obligations: The 10% reduction in royalty repayment amounts improves Jaguar Health’s financial flexibility and reduces future cash outflows. This could positively impact earnings and liquidity.
• Elimination of Dilutive Warrants: Terminating warrants that could have been converted into 48,211 shares means existing shareholders avoid dilution, potentially supporting the stock price.
• Minimum Monthly Royalty Payments: The commitment to a minimum monthly royalty payment creates a predictable financial obligation. Investors should assess how this impacts Jaguar Health’s cash flow projections and operational runway.
• No Defaults or Material Breaches: Jaguar Health affirms compliance and validity of its amended agreements, reducing legal and operational risk.

Exhibits Filed:

• Global Amendment No. 4 with Uptown and Streeterville Capital
• Amendment to the 2021 Note (Jaguar, Napo Pharmaceuticals, Streeterville)
• Amendment to the 2025 Note (Jaguar, Streeterville)
• Security Agreement (Napo Pharmaceuticals, Streeterville)
• Warrant Termination Agreement (Jaguar, Uptown, Streeterville, Iliad)

Potential Share Price Impact:

• These changes are likely to be price sensitive: the reduction in financial obligations and elimination of dilution are positives for shareholders and may be viewed favorably by the market.
• Investors should monitor Jaguar Health’s future disclosures for updates regarding cash flow, business operations, and any additional amendments.

Disclaimer:

This article is for informational purposes only and does not constitute investment advice. Investors should perform their own due diligence and consult with financial advisors before making investment decisions related to Jaguar Health, Inc. The information provided is based on public SEC filings and may be subject to change.

View Jaguar Health, Inc. Historical chart here